分组1 - Insulet reported quarterly earnings of $1.55 per share, exceeding the Zacks Consensus Estimate of $1.48 per share, and showing an increase from $1.15 per share a year ago, resulting in an earnings surprise of +4.87% [1] - The company achieved revenues of $783.8 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.15%, and up from $597.5 million in the same quarter last year [2] - Insulet has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Insulet shares have declined approximately 13.3% since the beginning of the year, contrasting with the S&P 500's zero return [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.20 on revenues of $703.22 million, and for the current fiscal year, it is $6.09 on revenues of $3.22 billion [7] 分组3 - The Medical - Products industry, to which Insulet belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Insulet was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

分组1 - AtriCure reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +400.00% [1] - The company achieved revenues of $140.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.01% and increasing from $124.28 million year-over-year [2] - AtriCure has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 17.5% since the beginning of the year, compared to a decline of 0.1% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.09 for the coming quarter and $0.02 for the current fiscal year [7] - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 40% of Zacks industries, which may impact stock performance [8]

Core Insights - Zimmer Biomet (ZBH) reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.38 per share, and showing an increase from $2.31 per share a year ago, resulting in an earnings surprise of +1.70% [1] - The company achieved revenues of $2.24 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.87% and up from $2.02 billion year-over-year [2] Earnings Performance - Over the last four quarters, Zimmer has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company also topped consensus revenue estimates three times in the same period [2] Stock Performance and Outlook - Zimmer shares have declined approximately 0.2% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [4][6] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $1.88 on revenues of $2.05 billion, and for the current fiscal year, it is $8.41 on revenues of $8.54 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which could impact Zimmer's performance [5]

Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying stocks that can sustain this growth is challenging due to associated risks and volatility [1] Group 1: Company Overview - Insulet (PODD) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company specializes in insulin infusion systems, which positions it well in the healthcare sector [3] Group 2: Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 51% this year, significantly surpassing the industry average of 11.2% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Insulet is 17.4%, exceeding the industry average of 3.5% [5] - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.9% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Insulet have been revised upward, with a 0.1% increase in the Zacks Consensus Estimate over the past month [7] Group 5: Investment Potential - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating its potential as an outperformer and a solid choice for growth investors [9]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - Insulet (PODD) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company specializes in insulin infusion systems, which positions it well within the healthcare sector [3] Group 2: Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 51% for the current year, significantly surpassing the industry average of 11.6% [5] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Insulet stands at 17.4%, exceeding the industry average of 3.6% [6] - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.5% [7] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Insulet have been revised upward, with a 0.1% increase in the Zacks Consensus Estimate over the past month [8] Group 5: Investment Potential - Insulet's combination of a Zacks Rank 2 and a Growth Score of A suggests it is a strong candidate for growth investors, indicating potential for outperformance [10]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 50.8% for the current year, significantly outperforming the industry average of 12.2% [5][4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, which is substantially higher than the industry average of 2.6%. Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.2% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 6% over the past month, indicating strong near-term stock price movement potential [8][10]. Overall Positioning - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, positioning it well for potential outperformance in the growth stock category [10].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Earnings Growth - Insulet has a historical EPS growth rate of 147.8%, with projected EPS growth of 43.8% this year, significantly outperforming the industry average of 13.5% [5] Cash Flow Growth - Insulet's year-over-year cash flow growth stands at 17.4%, well above the industry average of 2.5%. The company's annualized cash flow growth rate over the past 3-5 years is 51.1%, compared to the industry average of 8.2% [6][7] Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 0.5% over the past month [9] Overall Positioning - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating strong potential for outperformance in the growth stock category [11]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][8]. Earnings Growth - Insulet has a historical EPS growth rate of 147.8%, with projected EPS growth of 43% this year, significantly outperforming the industry average of 15% [4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, compared to an industry average of -0.1%, indicating strong cash generation capabilities [5]. - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, well above the industry average of 8.2% [6]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 0.9% over the past month [7]. Overall Assessment - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, making it a compelling option for growth investors [8][9].